You just read:

Savara Pharmaceuticals' AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis

News provided by

Savara Pharmaceuticals

Feb 23, 2015, 08:00 ET